DiemunschP, SchoefflerP, BryssineB, et al.Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery. Br J Anaesth, 1999; 82(2):274–276; doi: 10.1093/bja/82.2.274
2.
MathewSJ, VythilingamM, MurroughJW, et al.A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol, 2011; 21(3):221–229; doi: 10.1016/j.euroneuro.2010.11.012
3.
FurmarkT, AppelL, MichelgårdÅ, et al.Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist gr205171, citalopram, or placebo. Biol Psychiatry, 2005; 58(2):132–142; doi: 10.1016/j.biopsych.2005.03.029
4.
RoyaY, ToobaG. Substance p potentiates TGF-β1 production in lung epithelial cell lines. Iranian Journal of Allergy, Asthma and Immunology, 2009; 19–24.
5.
NewellFW, StarkP, JayWM, et al.Nabilone: A pressure-reducing synthetic benzopyran in open-angle glaucoma. Ophthalmology, 1979; 86(1):156–160; doi: 10.1016/S0161-6420(79)35539-7
6.
ErttmannSF, HärtlovaA, SlonieckaM, et al.Loss of the DNA damage repair kinase ATM Impairs Inflammasome-Dependent Anti-Bacterial innate immunity. Immunity, 2016; 45(1):106–118; doi: 10.1016/j.immuni.2016.06.018
7.
ChandyKG, DeCourseyTE, CahalanMD, et al.Voltage-gated potassium channels are required for human T lymphocyte activation. J Exp Med, 1984; 160(2):369–385; doi: 10.1084/jem.160.2.369
8.
McCubbinS, MeadeA, HarrisonDA, et al.Acute lipopolysaccharide (LPS)-induced cell membrane hyperpolarization is independent of voltage gated and calcium activated potassium channels. Comp Biochem Physiol C Toxicol Pharmacol, 2024; 285:110004; doi: 10.1016/j.cbpc.2024.110004
9.
Calcagni’A, StaianoL, ZampelliN, et al.Loss of the batten disease protein CLN3 leads to mis-trafficking of M6PR and defective autophagic-lysosomal reformation. Nat Commun, 2023; 14(1):3911; doi: 10.1038/s41467-023-39643-7
10.
Franco-JuárezB, Coronel-CruzC, Hernández-OchoaB, et al.TFEB; beyond its role as an autophagy and lysosomes regulator. Cells, 2022; 11(19):3153; doi: 10.3390/cells11193153
AbdiG, JainM, PatilN, et al.14-3-3 proteins—a moonlight protein complex with therapeutic potential in neurological disorder: In-depth review with Alzheimer’s disease. Front Mol Biosci, 2024; 11:1286536; doi: 10.3389/fmolb.2024.1286536
13.
SegalD, MaierS, MastromarcoGJ, et al.A central chaperone-like role for 14-3-3 proteins in human cells. Mol Cell, 2023; 83(6):974–993.e15; doi: 10.1016/j.molcel.2023.02.018
14.
GanneA, MainaliN, BalasubramaniamM, et al.Ezetimibe lowers risk of Alzheimer’s and related dementias over sevenfold, reducing aggregation in model systems by inhibiting 14-3-3G::hexokinase interaction. Aging Biol, 2024; 2:20240028; doi: 10.5936/8/agingbio.20240028
15.
SadeghiMA, NassireslamiE, Yousefi ZoshkM, et al.Phosphodiesterase inhibitors in psychiatric disorders. Psychopharmacology (Berl), 2023; 240(6):1201–1219; doi: 10.1007/s00213-023-06361-3
16.
ChenL, LiuK, WangY, et al.Phosphodiesterase-2 inhibitor reverses post-traumatic stress induced fear memory deficits and behavioral changes via cAMP/cGMP pathway. Eur J Pharmacol, 2021; 891:173768; doi: 10.1016/j.ejphar.2020.173768
17.
PanX, ChenL, ShanC, et al.Inhibition of Phosphodiesterase 2 Ameliorates Post-Traumatic Stress–Induced Alcohol Intake Disorder by Regulating cAMP/cGMP Signaling. Int J Neuropsychopharmacol, 2022; 25(11):936–945; doi: 10.1093/ijnp/pyac064
18.
BrysonHM, PalmerKJ, LangtryHD, et al.Propafenone. Drugs, 1993; 45(1):85–130; doi: 10.2165/00003495-199345010-00008
19.
KryshtalDO, BlackwellDJ, EglyCL, et al.RYR2 channel inhibition is the principal mechanism of flecainide action in CPVT. Circ Res, 2021; 128(3):321–331; doi: 10.1161/CIRCRESAHA.120.316819
HuhS, JungE, LeeJ, et al.Mechanisms of melanogenesis inhibition by propafenone. Arch Dermatol Res, 2010; 302(7):561–565; doi: 10.1007/s00403-010-1059-y
22.
ShresthaS, WangB, DuttaPK. Commercial silver-based dressings: In vitro and clinical studies in treatment of chronic and burn wounds. Antibiotics (Basel), 2024; 13(9):910; doi: 10.3390/antibiotics13090910
TiwariS, GuptaP, SinghA, et al.4-Phenylbutyrate mitigates the motor impairment and dopaminergic neuronal death during parkinson’s disease pathology via targeting VDAC1 mediated mitochondrial function and astrocytes activation. Neurochem Res, 2022; 47(11):3385–3401; doi: 10.1007/s11064-022-03691-0
25.
Guzmán MendozaNA, HommaK, OsadaH, et al.Neuroprotective effect of 4-phenylbutyric acid against photo-stress in the retina. Antioxidants (Basel), 2021; 10(7):1147; doi: 10.3390/antiox10071147
26.
RoczkowskyA, DoanMAL, HlavayBA, et al.Peroxisome injury in multiple sclerosis: Protective effects of 4-phenylbutyrate in CNS-Associated macrophages. J Neurosci, 2022; 42(37):7152–7165; doi: 10.1523/JNEUROSCI.0312-22.2022
27.
VandeVredeL, LjubenkovPA, RojasJC, et al.Four-Repeat tauopathies: Current management and future treatments. Neurotherapeutics, 2020; 17(4):1563–1581; doi: 10.1007/s13311-020-00888-5
28.
WangH, LuM, ZhaiS, et al.ALW peptide ameliorates lupus nephritis in MRL/lpr mice. Arthritis Res Ther, 2019; 21(1):261; doi: 10.1186/s13075-019-2038-0
29.
LiW, YaoC, GuoH, et al.Macrophages communicate with mesangial cells through the CXCL12/DPP4 axis in lupus nephritis pathogenesis. Cell Death Dis, 2024; 15(5):1–13; doi: 10.1038/s41419-024-06708-4
30.
MayerA-L, ScheitackerI, EbertN, et al.The DPP4 inhibitor linagliptin ameliorated renal injury and accelerated resolution in a rat model of crescentic nephritis. Br J Pharmacol, 2021; 178(4):878–895; doi: 10.1111/bph.15320
31.
HigashijimaY, TanakaT, YamaguchiJ, et al.Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury. Am J Physiol Renal Physiol, 2015; 308(8):F878–F887; doi: 10.1152/ajprenal.00590.2014
MatthewsT, BoehmeR. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis, 1988; 10 (Suppl 3):S490–S494; doi: 10.1093/clinids/10.supplement_3.s490
34.
RamadhaniA, AstutiI, WidiastutiMG, et al.Methylcobalamin as a candidate for chronic peripheral neuropathic pain therapy: Review of molecular pharmacology action. Korean J Pain, 2024; 37(4):299–309; doi: 10.3344/kjp.24171
35.
OkiR, IzumiY, FujitaK, et al.Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for ALS (JETALS) Collaborators. Efficacy and Safety of Ultrahigh-Dose methylcobalamin in early-stage amyotrophic lateral sclerosis: A randomized clinical trial. JAMA Neurol, 2022; 79(6):575–583; doi: 10.1001/jamaneurol.2022.0901
36.
LiaoX-X, DaiY-Z, ZhaoY-Z, et al.Gasdermin E: A prospective target for therapy of diseases. Front Pharmacol, 2022; 13:855828; doi: 10.3389/fphar.2022.855828
37.
Al MamunA, WuY, JiaC, et al.Role of pyroptosis in liver diseases. Int Immunopharmacol, 2020; 84:106489; doi: 10.1016/j.intimp.2020.106489
BarbieroJK, RamosDC, BoschenS, et al.Fenofibrate promotes neuroprotection in a model of rotenone-induced Parkinson’s disease. Behav Pharmacol, 2022; 33(8):513–526; doi: 10.1097/FBP.0000000000000699
40.
GrabackaM, WieczorekJ, Michalczyk-WetulaD, et al.Peroxisome proliferator-activated receptor α (PPARα) contributes to control of melanogenesis in B16 F10 melanoma cells. Arch Dermatol Res, 2017; 309(3):141–157; doi: 10.1007/s00403-016-1711-2
41.
MarquesC, RamalhoJS, PereiraP, et al.Bendazac decreases in vitro glycation of human lens crystallins. Decrease of in vitro protein glycation by bendazac. Doc Ophthalmol, 1995; 90(4):395–404; doi: 10.1007/BF01268125
42.
TestaM, IulianoG, MarinoE, et al.Bendazac and benzydamine for treatment of cataract: Individualized therapy by the “BLOA test.” J Ocul Pharmacol, 1986; 2(3):251–266; doi: 10.1089/jop.1986.2.251
43.
MedieroA, WilderT, Perez-AsoM, et al.Direct or indirect stimulation of adenosine A2A receptors enhances bone regeneration as well as bone morphogenetic protein-2. Faseb J, 2015; 29(4):1577–1590; doi: 10.1096/fj.14-265066
44.
LiraEC, GonçalvesDAP, Parreiras-E-SilvaLT, et al.Phosphodiesterase-4 inhibition reduces proteolysis and atrogenes expression in rat skeletal muscles. Muscle Nerve, 2011; 44(3):371–381; doi: 10.1002/mus.22066
45.
GaoG, ZhaoS, XiaX, et al.Glutaminase C Regulates Microglial Activation and Pro-inflammatory Exosome Release: Relevance to the Pathogenesis of Alzheimer’s Disease. Front Cell Neurosci, 2019; 13:264; doi: 10.3389/fncel.2019.00264
46.
LiX, ShongK, KimW, et al.Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach. eBioMedicine, 2022; 78:103963; doi: 10.1016/j.ebiom.2022.103963
47.
BayraktarA, LiX, KimW, et al.Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer’s disease patients. J Transl Med, 2023; 21(1):332; doi: 10.1186/s12967-023-04192-6
48.
SunL, PengY, YuW, et al.Mechanistic insight into antiretroviral potency of 2′-Deoxy-2′-β-fluoro-4′-azidocytidine (FNC) with a long-lasting effect on HIV-1 prevention. J Med Chem, 2020; 63(15):8554–8566; doi: 10.1021/acs.jmedchem.0c00940
49.
WangQ, LiuX, WangQ, et al.FNC, a novel nucleoside analogue inhibits cell proliferation and tumor growth in a variety of human cancer cells. Biochem Pharmacol, 2011; 81(7):848–855; doi: 10.1016/j.bcp.2011.01.001
50.
Bugarski-KirolaD, BlaettlerT, ArangoC, et al.Bitopertin in negative symptoms of schizophrenia—results from the phase III flashlyte and daylyte studies. Biol Psychiatry, 2017; 82(1):8–16; doi: 10.1016/j.biopsych.2016.11.014
